EUVIMEDEUVIMED entdecken
Crossref

Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments

Ting-Wei Lyu, Wei-Yih Chiu, Ting Sun, Sheng-Chieh Chou

Haemophilia · 2026

DOI: 10.1111/hae.70215 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2026. Verfasst von Ting-Wei Lyu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Hemophilia A, Bone Density, Antibodies, Monoclonal, Humanized, Antibodies, Bispecific. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Taiwan University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Haemophilia, an X‐linked disorder, is linked to reduced bone mineral density (BMD). Emicizumab, a factor VIII (FVIII) mimetic, provides a model to study the role of FVIII in bone health.

Aim

To evaluate BMD in adults with severe haemophilia under different prophylactic regimens, focusing on whether emicizumab maintains bone health comparable to FVIII prophylaxis.

Methods

Forty male adults with severe haemophilia A or B were prospectively enrolled at a single centre (2019–2024) and assigned to five prophylactic groups: emicizumab (with/without inhibitors), FVIII, factor IX (FIX) or investigational agents. Annual assessments included dual‐energy X‐ray absorptiometry, joint status, mobility and bone turnover markers.

Results

Of the 40 patients, 18 received FVIII, 10 FIX, 4 haemophilia A with inhibitors on emicizumab, 4 haemophilia A without inhibitors on emicizumab and 4 investigational therapies. At baseline, spine BMD z‐scores were comparable to age‐matched norms, whereas hip BMD was significantly lower (median –0.8; p < 0.001). After 1 year, spine and hip BMD changes did not differ significantly across treatment groups ( p = 0.9010 and p = 0.8073, respectively). Lower annual bleeding rate, middle age and BMI extremes were associated with BMD improvement. Emicizumab‐treated patients, with or without inhibitors, showed non‐inferior BMD outcomes compared to those receiving FVIII, with all 95% confidence intervals within the predefined margin (±0.5).

Conclusion

BMD outcomes did not differ across regimens. Emicizumab was comparable to FVIII, suggesting bleed control, not factor replacement, is key to bone health in haemophilia. Plain Language Summary People with haemophilia often have problems with joint bleeding, which can limit movement and reduce bone strength. Different treatments are now available to prevent bleeding, including factor replacement and newer medicines such as emicizumab. It is not clear whether these treatments affect bone health differently. In this study, we followed 40 adults with haemophilia and measured their bone health for 1 year. We found that bone outcomes were similar across all treatment groups. Emicizumab worked just as well as factor VIII in maintaining bone strength. This means that good bleeding control may be the key to keeping bones healthy in haemophilia, regardless of the treatment type.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia ABone DensityAntibodies, Monoclonal, HumanizedAntibodies, BispecificHemophilia BHumansMaleAdultMiddle AgedFactor VIIIYoung AdultFactor IX

Stichwörter der Autor:innen

bone healthbone mineral densityemicizumabhaemophilianon‐factor therapyosteoporosis

Substanzen

emicizumabAntibodies, Monoclonal, HumanizedAntibodies, BispecificFactor VIIIFactor IX

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
  • Division of Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.

Förderung

  • National Taiwan University Hospital

Zitieren

APA

Lyu, T. W., Chiu, W. Y., Sun, T., & Chou, S. C. (2026). Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments. Haemophilia. https://doi.org/10.1111/hae.70215

Vancouver

Lyu TW, Chiu WY, Sun T, Chou SC. Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments. Haemophilia. 2026. doi:10.1111/hae.70215

BibTeX
@article{Lyu2026,
  author = {Lyu, Ting-Wei and Chiu, Wei-Yih and Sun, Ting and Chou, Sheng-Chieh},
  title = {Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments},
  journal = {Haemophilia},
  year = {2026},
  doi = {10.1111/hae.70215}
}
Kostenlos starten →